Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/ALK-Positive Lung Cancer

Rare Cancers

ALK-Positive Lung Cancer Clinical Trials and Treatments

Also called ALK-positive non-small cell lung cancer, ALK-positive NSCLC, ALK-rearranged lung cancer, ALK-rearranged NSCLC, ALK+ lung cancer, EML4-ALK lung cancer

In ALK-positive lung cancer, a piece of the ALK gene breaks off inside the tumor cells. It joins another gene, most often one called EML4.

In plain words, ALK-positive lung cancer is a lung cancer driven by a change in the ALK gene that happens inside the tumor and is not inherited. Daily pills that block ALK are the main treatment, and newer ones work after the cancer gets around an earlier drug.

Get an email when new ALK-Positive Lung Cancer trials open or the FDA decides. Get alerts

ALK-Positive Lung Cancer

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines7

Nelkarmi · Lorbrena · Alecensa · Alunbrig · Ensacove · 2 more

ALK-Positive Lung Cancer has 7 FDA-approved medicines, 44 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for ALK-Positive Lung Cancer

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about ALK-Positive Lung Cancer

The fused gene makes a protein that keeps telling the cells to grow, according to LUNGevity and the National Cancer Institute. The change happens during life in the tumor only and is not passed on in families.

Keep reading about ALK-Positive Lung Cancer

The ALK change is found by testing the tumor. ALK Positive says experts recommend next-generation sequencing (NGS) as part of any biomarker testing, because FISH and immunohistochemistry check only a few gene changes. It also says US guidelines recommend comprehensive biomarker testing for everyone diagnosed with non-small cell lung cancer. LUNGevity calls a tissue biopsy the standard when enough tissue is available. The Alecensa label says that when a blood test does not find an ALK change, tumor tissue should be tested if possible. ALK-positive lung cancer often spreads to the brain. In a 2015 Boston study from before the newer ALK drugs, 23.8% of 21 people with advanced ALK-positive cancer had brain metastases when advanced disease was found. Among those still alive at 3 years, 58.4% had them (Rangachari et al., 2015).

The main treatment for advanced disease is a daily ALK inhibitor pill. The American Cancer Society says lorlatinib, alectinib, brigatinib, ceritinib and ensartinib are often the preferred first treatment. It says alectinib is also used after surgery for some early-stage cancers. It adds that crizotinib, the first of these drugs, is still used in some situations. Over time the cancer often changes the ALK protein in ways that stop a drug from working. Each drug tends to leave behind its own resistance changes, such as G1202R (Gainor et al., 2016). This is why LUNGevity says doctors often recommend a new biopsy before switching. On November 17, 2026 the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced cancer. It is for adults whose cancer grew after alectinib alone, or after 2 or more ALK inhibitors and platinum chemotherapy, given for advanced or metastatic disease.

What are the symptoms of ALK-Positive Lung Cancer?

These are common symptoms of ALK-Positive Lung Cancer, and how strong they are varies from person to person.

  • A cough that does not go away or gets worse
  • Chest pain or discomfort, and trouble breathing or wheezing
  • Coughing up blood, or hoarseness
  • Tiredness, loss of appetite and weight loss without a known reason
  • Headaches, weakness or seizures if the cancer has spread to the brain
  • No symptoms at all until the cancer has spread, which ALK Positive says is common

Who gets ALK-Positive Lung Cancer?

ALK-positive lung cancer is usually found at a younger age than lung cancer overall. LUNGevity gives a median age at diagnosis of 52 for ALK-positive non-small cell lung cancer. The median age was 56 among the 656 people in the trial behind the Nelkarmi approval, according to its label. For comparison, the American Cancer Society puts the average age at diagnosis for all lung cancer at about 70. ALK Positive says 2 out of 3 people with ALK-positive lung cancer never smoked. The National Cancer Institute says EGFR and ALK changes predominate in adenocarcinomas that develop in nonsmokers. The ALK change is acquired in the tumor and is not inherited, according to LUNGevity.

Next steps: find trials you might fitcompare treatmentsget help payingget alerts

Which medicines are FDA-approved for ALK-Positive Lung Cancer?

There are currently 7 FDA-approved medications for ALK-Positive Lung Cancer.

neladalkib
Nuvalent, Inc. (GSK)
Search
lorlatinib
Pfizer
Search
alectinib
Genentech (Roche)
Search
brigatinib
Takeda
Search
ensartinib
Xcovery Holdings
Search
crizotinib
Pfizer
Search
ceritinib
Novartis
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for ALK-Positive Lung Cancer treatment

Charity funds and drugmaker programs for ALK-Positive Lung Cancer, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.

Every program and fund for ALK-Positive Lung Cancer, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for ALK-Positive Lung Cancer

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted ALK-Positive Lung Cancer resources

Reputable organizations and medical references for learning more about ALK-Positive Lung Cancer, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for ALK-Positive Lung Cancer

Use this ALK-Positive Lung Cancer clinical trial finder to see the 12 studies recruiting patients and 8 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 16 test a treatment and 4 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

44 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 1Recently updatedNCT07140016

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Intervention: gilteritinib

Sponsor: Astellas Pharma Global Development, Inc.

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stand...

Ages 18 Years+
Started Sep 2025Updated yesterdayEst. Dec 2029 (~3y 1m)
RecruitingTreatment trialPhase 1/2Recently updatedNCT07491497

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Intervention: TRI-611

Sponsor: TRIANA Biomedicines, Inc.

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC.

Ages 18 Years+
Started Mar 2026Updated 2 days agoEst. May 2029 (~2y 6m)
Not yet recruitingTreatment trialPhase 1Recently updatedNCT07938463

Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC

Intervention: TNG462 vopimetostat, Lorlatinib

Sponsor: Dana-Farber Cancer Institute · Tango Therapeutics, Inc.

TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. Th...

Ages 18 Years+2 locations
Expected to start Apr 2027Updated 5 days agoEst. Nov 2027 (~1 year)
RecruitingObservational study, no treatment givenRecently updatedNCT06862869

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Intervention: Alectinib

Sponsor: Hoffmann-La Roche

This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.

Ages 18 Years+
Started Apr 2025Updated 2 weeks agoEst. Oct 2029 (~2y 11m)
Not yet recruitingTreatment trialPhase 1Recently updatedNCT07912268

Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Intervention: SIM0518, SIM0518+Bupropion, SIM0518+Midazolam, SIM0518+Repaglinide, SIM0518+Tolbutamide, SIM0518+Fexofenadine, SIM0518+ Rosuvastatin Calcium

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

This is a multicenter, open-label, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic /pharmacodynamic characteristics of SIM0518 in trial participants with ALK-positive or ROS1-positive locally advanced or metastatic Non-Small Cell Lung Ca...

Ages 18 Years+
Expected to start Nov 2026Updated 2 weeks agoEst. Dec 2028 (~2 years)
Find ALK-Positive Lung Cancer trials near you, ranked by distance →
Active trial locations36 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+28 more

Trial Pipeline

Sep 2023 to Nov 2031
2024
2026
2028
2030
now
Phase 1
Phase 2
Phase 3
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about ALK-Positive Lung Cancer trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run an ALK-Positive Lung Cancer foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

ALK-Positive Lung Cancer patient communities

Facebook groups, Reddit communities and YouTube channels where ALK-Positive Lung Cancer patients, caregivers and advocacy groups talk.

ALK-Positive Lung Cancer news and guides

Trial Friend articles about ALK-Positive Lung Cancer, newest first

Companies developing ALK-Positive Lung Cancer treatments

Drugmakers that list ALK-Positive Lung Cancer in their rare disease portfolio, 5 in all.

Questions people ask about ALK-Positive Lung Cancer